The Nordic urinary catheters market stood at USD 82.11million in 2025 and is on track to climb from USD 87.20million in 2026 to USD 141.09 million by 2034, translating to a compound annual growth rate (CAGR) of 6.20% over the 2026–2034 forecast window, according to Fortune Business Insights. Sweden is the clear leader among Nordic countries, accounting for over a third of the regional market in 2022.
A urinary catheter is a medical device inserted through the urethra into the bladder to drain urine, commonly used to manage urinary incontinence and retention. Demand across the Nordics is being shaped largely by demographic and clinical trends rather than by aging alone — chronic disease burden and rising surgical volumes are equally significant contributors.
Key Growth Drivers
Two forces stand out as the primary engines of market expansion:
Rising incidence of urinary incontinence and related conditions. Enlarged prostate, diabetes, and Parkinson's disease are common contributors to incontinence in men, while pregnancy, childbirth, and menopause-related hormonal shifts drive prevalence among women. Denmark illustrates the scale of the issue starkly, with incontinence affecting an estimated 46% of women in the country.
Growth in surgical procedures and hospital admissions. Catheterization is now considered routine practice in cardiac surgery and other major procedures, since urine output serves as an indirect marker of a patient's renal, cardiovascular, and fluid status during recovery. Sweden's healthcare data underscore this link between hospital activity and catheter demand: heart failure patients there average multiple annual admissions with hospital stays running roughly a week.
The region's aging population reinforces both drivers. Sweden alone has roughly a fifth of its population above retirement age, a figure expected to rise further by 2040, while home-care services already support hundreds of thousands of elderly citizens nationally.
Get a Free Sample PDF - https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/nordic-urinary-catheters-market-108559
Restraining Factors
Catheter-associated urinary tract infections (CAUTIs) remain the market's biggest headwind. Indwelling catheters in particular carry infection risk when used over extended periods, and healthcare-associated infection surveys in Swedish hospitals have found urinary tract infections responsible for roughly a fifth of all reported hospital-acquired infections. Lingering social stigma around UTIs compounds the reluctance to adopt these devices in some patient populations.
Segment Trends
By product type, intermittent catheters command the leading share. Because they're removed after each use rather than left in place, they carry a materially lower CAUTI risk than indwelling devices — a distinction that has made intermittent catheterization something close to the clinical gold standard. Indwelling catheters retain a strong foothold in long-term care and gynecological or reconstructive surgical settings, while external (condom) catheters, though currently a smaller segment, are gaining traction because they can be used safely outside clinical settings and cause less urethral trauma.
By application, urinary incontinence is the dominant use case, followed by surgery-related use. Benign prostatic hyperplasia and gynecological applications are both expected to see steady expansion, the latter linked to rising rates of ovarian and bladder cancer surgery.
By gender, male patients account for the larger share of the market, driven by conditions such as prostate cancer, benign prostatic hyperplasia, and spinal cord injury — the latter overwhelmingly affecting men in Nordic injury data. Female adoption is comparatively tempered by the availability of cheaper alternatives like adult diapers for managing incontinence.
By end-user, hospitals dominate given rising admission volumes and expanding healthcare infrastructure, while age care centers and home-care settings are projected to grow at a faster pace, reflecting the broader regional shift toward assisted and home-based elderly care.
Country-Level Dynamics
Sweden led the region with a 2022 market value of USD 24.5 million, underpinned by high hospital admission rates and a publicly financed healthcare system offering broad coverage. Norway's market benefits from strong healthcare infrastructure and a notably high incidence of traumatic spinal cord injury among men. Denmark's growth is closely tied to its high female incontinence prevalence and the presence of domestic manufacturer Coloplast A/S. Finland, along with the smaller Nordic markets, continues to expand on the back of improving reimbursement frameworks and infrastructure.
Competitive Landscape
The market remains fragmented, with Coloplast A/S, Wellspect HealthCare (Dentsply Sirona), BACTIGUARD, B. Braun, and ConvaTec among the leading players, alongside Teleflex, Hollister, and BD. Recent innovation has centered on infection-reduction features and sustainability — Coloplast's Luja catheter uses micro-hole technology to lower UTI risk, while Wellspect has introduced bioplastic components in its LoFric Elle line to cut the product's carbon footprint.